A novel drug-eluting stent using bioabsorbable polymer technology: Two-year follow-up of the CURAMI registry

International Journal of Cardiology

Volumn 131, Issue 2, 2009, Pages 272-274

  Tin Hay, Eduardo ^a   Hou, Xu Min ^a   Lim, Jimmy ^a   Low, Adrian ^a   Teo, Swee Guan ^a   Tan, Huay Cheem ^a   Lee, Chi Hang ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Bioabsorbable; Coronary; Drug eluting stent; Polymer; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; POLYGLACTIN; POLYLACTIC ACID; POLYMER; RAPAMYCIN;

ACUTE HEART INFARCTION; ADULT; AGED; ALLERGY; ANGIOCARDIOGRAPHY; ARTICLE; BIODEGRADABLE IMPLANT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; RESTENOSIS; STENT THROMBOSIS; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POLYMERS; REGISTRIES;

EID: 57549093470     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.07.074     Document Type: Article

References (14)

1. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
2. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27 (2006) 2784-2814
3. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
4. Bavry A.A., Kumbhani D.J., Helton T.J., et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
5. Lagerqvist B., James S.K., Stenestrand U., et al., SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
6. Serruys P.W., Sianos G., Abizaid A., et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 46 (2005) 253-260
7. Costa R.A., Lansky A.J., Abizaid A., et al. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol 98 (2006) 443-446
8. Costa R.A., Lansky A.J., Mintz G.S., et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 95 (2005) 113-116
9. Lee C.H., Lim J., Low A., et al. A Sirolimus-eluting, bioabsorbable polymer-coated constant stent (Cura™) in acute ST-elevation myocardial infarction: a clinical and angiographic study (CURAMI Registry). J Invasive Cardiol 19 (2007) 182-185
10. Finn A.V., Kolodgie F.D., Harnek J., et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 (2005) 270-278
11. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
12. Kotani J., Awata M., Nanto S., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (2006) 2108-2111
13. Azarbal B., and Currier J.W. Allergic reactions after the implantation of drug-eluting stents: is it the pill or the polymer?. J Am Coll Cardiol 47 (2006) 182-183
14. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168